Ann: Notice of Extraordinary General Meeting/Proxy Form, page-69

First 69 Last

Share
Profile

Follow
Rod_Valens

1,190 Posts.

176

27/03/19

21:36

Post #: 37906627
Share

Originally posted by mg97788: ↑

I tend to agree galilee

My main concern with this stock was cash levels and leverage, the capital raise was 100% necessary and looks to be an appropriate level of cash to fund and grow the company over the next 2 - 3 years - whilst also releasing a substantial amount of debt. Company for mine continues to de-risk.

The company is spending around US$4mio a quarter.... likely to pick up in the next few months. Revenue growth last quarter was 100% - so if the company can achieve that run rate next 2 quarters it will be generating USD5.5mio a quarter. This effectively should be achieved with the Hygea contract - even assuming no further sales contracts coming on. If you add in another Hygea size contract - the company will be getting close to US$40mio revenue per annum (US10mio per quarter). However, cash burn has been heavy, will likely pick up in the next two-three quarters as well as the company ramps up production and marketing - so hard to estimate, and hence the need to capital raise

If you use IRYTHM as a comp - they did US130mio revenue last year (as Low Key mentioned) - market cap of US2bio. So US40mio vs US130mio is about 30% of revenue - 30% of 2bio market cap is 615mio US or AU850mio.

This is just the way im viewing it, and despite the dilution, im happy the leverage is coming out of the company and there is sufficient cash to fund the next 2-3 years of growth.

Im looking for another HYGEA size announcement, increasing revenue growth quarter on quarter in the next 4C and the CFDA approval to hopefully turn the Silverlake MOU to a contract as well.

These are the key requirements for a re-rate of the stock, but as a risk reward trade i like my odds.

DYOR

Expand

Great post MG, I would also add the strong commitment of Yacov with his/our company. He converted what has been withdrawn ~$5m from his loan to GMV to shares! This is unbelievable, this on top of the $1m he bought from the open market. I have never seen this level of commitment from a CEO, specially when those shares will probably never hit the market.

GMV Price at posting: 28.5¢ Sentiment: Buy Disclosure: Held
20 Upvote

5 Great analysis

Reply

Top Stories

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

HotCopper Highlights: Your most watched stocks for Week 47, 2024

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 21 more messages in this thread...

First 69 Last

Add GMV (ASX) to my watchlist

Ann: Notice of Extraordinary General Meeting/Proxy Form, page-69

Top Stories

Scientific conference spotlights PYC's work on blindness disease treatment

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Sales growth pushes Lovisa's fortunes (and shares) upwards

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up